New York City, NY: October 22, 2019 Published via (Wired Release) Essential Business Strategies Global Cryonics Technology Market provides extensive research and detailed analysis of the present market along with future outlook. The report content includes orientation technology, market, drivers, geographic trends, market statistics, market estimates, producers, and equipment suppliers of cryonics technology industry. It also profiles and analyzes the leading companies and several other prominent companies operating in the Cryonics Technology Market. It also analyzes the industry future trends, risks, and entry barriers, status, development rate, cryonics technology market factors, opportunities and challenges, sales channels, distributors. It helps you understand the technical jargon that offers ease and convenience to you in understanding the report contents. The study provides detailed information on the established Cryonics Technology market with a clear perceptive of global market players and emerging market associations through market research reports.

Complete Analysis of the report contains the current market scenario as well as a market forecast till 2029. The forecast is also supported by the elements affecting the market dynamics for the forecast period. Various applications, product types, geographical regions, and market value are focused in this wide report scope. The study includes all active constraints, restraints, openings, market challenges and also outlines the historical data, current and future momentum of the market. The market is a widening field for top candidates including-Praxair, Cellulis, Cryologics, Cryotherm, KrioRus, VWR, Thermo Fisher Scientific, Custom Biogenic Systems, Oregon Cryonics, Alcor Life Extension Foundation, Osiris Cryonics, Sigma-Aldrich, Southern Cryonics.

Get Sample For Technological Breakthroughs (Use official eMail ID to Get Higher Priority) at: https://market.us/report/cryonics-technology-market/request-sample

Top Companies:

PraxairCellulisCryologicsCryothermKrioRusVWRThermo Fisher ScientificCustom Biogenic SystemsOregon CryonicsAlcor Life Extension FoundationOsiris CryonicsSigma-AldrichSouthern Cryonics

Split by product type, with production, revenue, price, market share and growth rate of each type, can be divided into:

Slow freezingVitrificationUltra-rapid

Split by application, this report focuses on consumption, market share and growth rate of the market in each application:

Animal husbandryFishery scienceMedical sciencePreservation of microbiology cultureConserving plant biodiversity

The regional segmentation covers:

North America Region (U.S., Canada, Mexico)

Europe Region (Germany, UK, France, Russia, Italy, Rest of Europe)

Asia-Pacific Region (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)

South America Region (Brazil, Argentina, Columbia, Rest of South America)

The Middle East & Africa Region (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)

Place An Inquiry Before Investment (Use Corporate Details Only): https://market.us/report/cryonics-technology-market/#inquiry

Report provides:

-Key Manufacturers and their strategy

-Emerging Segments and their sub-segments

-Major changes in the Global Cryonics Technology Market market

-Full in-depth analysis of the parent market

-Past, on-going, and projected market analysis in terms of volume and value

-Analysis of Global Cryonics Technology Market at regional level

-Evaluation of niche industry developments

Browse More Insight Of This Premium Research Report Enabled with Respective Tables and Figures @ https://market.us/report/cryonics-technology-market/

Global Cryonics Technology Market TOC (Table Of Content) Provides Following Market Segment:

Segment 1 Study Coverage

Segment 2 Executive Summary

Segment 3 Cryonics Technology Market Size by Manufacturers

Segment 4 Production by Regions

Segment 5 Consumption by Regions

Segment 6 Cryonics Technology Market Size by Type

Segment 7 Cryonics Technology Market Size by Application

Segment 8 Manufacturers Profiles

Segment 9 Production Forecasts

Segment 10 Consumption Forecast

Segment 11 Upstream, Industry Chain and Downstream Customers Analysis

Segment 12 Threat and Affecting Factors, Opportunities & Challenges

Segment 13 Key Findings

Segment 14 Appendix

Get More Reports From Other Reputed Sources:

https://www.marketwatch.com/press-release/global-peripheral-nerve-repair-market-status-and-prospect-forecast-2019-to-2028-2019-01-17https://www.marketwatch.com/press-release/global-healthcare-equipment-leasing-market-2019-business-overview-and-development-strategies-by-2028-2019-01-17

See the original post here:
Trends in Cryonics Technology Market Reviewed with 2027 Opportunities in New Research Report - TheLoop21

Recommendation and review posted by Bethany Smith

LEVERKUSEN, Germany and ZUG, Switzerland and CAMBRIDGE, Mass., Oct. 21, 2019 /PRNewswire/ -- CRISPR Therapeuticsand Bayer today announced proposed plans whereby Casebia Therapeutics, a joint venture between CRISPR Therapeutics and Bayer, would operate under the direct management of CRISPR Therapeutics. Upon closing of the transaction, Casebia Therapeutics would focus on the development of its lead programs in hemophilia, ophthalmology and autoimmune diseases, with Bayer having opt-in rights for two products at IND submission.

"The standalone Casebia entity combined the capabilities of CRISPR Therapeutics and Bayer to significantly advance the CRISPR/Cas9 gene-editing platform," said Samarth Kulkarni, Ph.D., Chief Executive Officer of CRISPR Therapeutics. "As Casebia's programs have advanced beyond the discovery stage, we are evolving the operating model to leverage the manufacturing and clinical expertise of CRISPR Therapeutics to further accelerate these programs."

"We remain excited about the potential of cutting-edge CRISPR/Cas9 based therapies, which have the potential to create a whole new class of medicines," said Kemal Malik, Bayer board member for Innovation. "CRISPR Therapeutics has built the capabilities and expertise necessary to advance the Casebia programs to the next phase of development, and we look forward to continuing our collaboration with them."

The transaction is subject to negotiation and execution of definitive agreements as well as certain customary conditions. The companies anticipate the transaction will close in the fourth quarter of 2019.

About CRISPR TherapeuticsCRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with leading companies including Bayer AG, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in London, United Kingdom. For more information, please visit http://www.crisprtx.com.

About Bayer and Leaps by BayerBayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Bayer's products and services are designed to benefit people by supporting efforts to overcome the major challenges presented by a growing and aging global population. At the same time, Bayer aims to increase its earning power and create value through innovation and growth. Bayer is committed to the principles of sustainable development, and the Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2018, the Bayer global group employed around 117,000 people and had sales of 39.6 billion euros. Capital expenditures amounted to 2.6 billion euros, R&D expenses to 5.2 billion euros. For more information, go towww.bayer.com.

Leaps by Bayer, a unit of Bayer is investing into solutions to some of today's biggest problems. Previous Leaps investments into potentially breakthrough technologies include BlueRock Therapeutics (iPSC technology to cure cardiovascular and CNS diseases), Joyn Bio (probiotics for plants to enable for chemical fertilizer-free farming), Khloris (iPSC as cancer vaccination agents for potential prevention or cure), Century Therapeutics (iPSCs for allogeneic cell therapy of cancer), and Pyxis Oncology (antibody-based immunotherapies targeting the tumor microenvironment).

CRISPR Forward-Looking StatementThis press release may contain a number of "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding CRISPR Therapeutics' expectations about any or all of the following: (i) the proposed transaction involving Casebia Therapeutics; (ii) the therapeutic value, development, and commercial potential of CRISPR/Cas-9 gene editing technologies and therapies, including in hemophilia,ophthalmology and for autoimmune diseases; and (iii) CRISPR Therapeutics' ability to leverage manufacturing and clinical expertise to meaningfully advance certain Casebia Therapeutics programs. Without limiting the foregoing, the words "believes," "anticipates," "plans," "expects" and similar expressions are intended to identify forward-looking statements. You are cautioned that forward-looking statements are inherently uncertain. Although CRISPR Therapeutics believes that such statements are based on reasonable assumptions within the bounds of its knowledge of its business and operations, forward-looking statements are neither promises nor guarantees and they are necessarily subject to a high degree of uncertainty and risk. Actual performance and results may differ materially from those projected or suggested in the forward-looking statements due to various risks and uncertainties. These risks and uncertainties include, among others: uncertainties inherent in corporate restructuring, including the expected timing for completion of such restructuring and the possibility that the parties will be unable to consummate any proposed transaction; the possibility that the expected synergies from CRISPR Therapeutics' manufacturing and clinical expertise will not be realized, or will not be realized within the expected time period; the risk that the businesses will not be integrated successfully; the initiation and completion of preclinical studies for CRISPR Therapeutics' and/or Casebia Therapeutics' product candidates; availability and timing of results from preclinical studies; whether results from a preclinical trial will be predictive of future results of the future trials; uncertainties about regulatory approvals to conduct trials or to market products; uncertainties regarding the intellectual property protection for CRISPR Therapeutics' technology and intellectual property belonging to third parties, and the outcome of proceedings (such as an interference, an opposition or a similar proceeding) involving all or any portion of such intellectual property; and those risks and uncertainties described under the heading "Risk Factors" in CRISPR Therapeutics' most recent annual report on Form 10-K, and in any other subsequent filings made by CRISPR Therapeutics with the U.S. Securities and Exchange Commission, which are available on the SEC's website at http://www.sec.gov. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date they are made. CRISPR Therapeutics disclaims any obligation or undertaking to update or revise any forward-looking statements contained in this press release, other than to the extent required by law.

CRISPR Therapeutics Investor Contact:Susan Kimsusan.kim@crisprtx.com

CRISPR Therapeutics Media Contact:Jennifer PaganelliWCG on behalf of CRISPR347-658-8290jpaganelli@wcgworld.com

Bayer Media Contact:Chris Loder(201) 396-4325Christopher.loder@bayer.com

SOURCE Bayer

http://www.bayer.com

The rest is here:
CRISPR Therapeutics and Bayer Announce an Update on Casebia Therapeutics - PRNewswire

Recommendation and review posted by Bethany Smith

Mon, Oct 21, 2019 - 5:50 AM

New York

AS investors await results from the first US clinical trials of the gene-editing system known as Crispr, scientists are focused on finding ways to administer it directly into humans, according to the technology's co-inventor, Jennifer Doudna.

Right now, in studies using Crispr that have treated patients, researchers have had to extract their cells to be able to make edits to faulty DNA before infusing them back into the body for treatment.

Being able to do precise edits directly inside humans, animals or plants could open the door to new applications, Ms Doudna said.

"With advances and delivery techniques, it may be possible to do that kind of very highly efficient targeted genome editing in the patient, without having to remove cells, but actually to just do a treatment in the patient where the delivery vehicle takes the editing molecule to the right cells," she said in an interview before the Welch Foundation Conference on chemical research this week.

"Sounds fantastical today, but I think that's coming."

In essence, Crispr is a gene-editing system that can splice away parts of human DNA that make people susceptible to disease or defects. While it can be used in plants and animals, scientists are working on therapeutic applications that can offer a one-time cure for certain diseases.

Crispr Therapeutics AG was the first company to start a human trial back in February, and is due to report initial results by year-end.

Editas Medicine Inc is leading efforts in "in-vivo", or inside the body, testing and initiated a clinical study in July. Intellia Therapeutics Inc is expected to follow with its own study next year.

A safe delivery of Crispr directly into humans would shorten manufacturing times and offer new opportunities for the companies.

The biggest challenge is to find a way to deliver gene-editing molecules into specific cell types safely and efficiently, Ms Doudna said.

"That's kind of the next frontier," she added. "If we figure that out, it really does open the way to many, many more kinds of applications in genome editing than are possible today."

Crispr and Intellia Therapeutics have licensed their technology from the University of California at Berkeley, Ms Doudna's academic home, while Editas is using inventions from the Broad Institute in Massachusetts.

The two institutions are fighting over who was first to invent breakthrough gene-editing technology. Ms Doudna is a co-founder of Editas and other Crispr startups and is a scientific board member at Intellia.

The gene-editing field, which only recently entered human testing and has been plagued by research raising safety concerns, recently got some encouraging news.

Chinese researchers safely treated a man with leukemia and HIV using gene-edited stem cells, according to a report in the New England Journal of Medicine. While the attempt to cure his HIV failed, his cancer is in remission 19 months after the treatment, and the modified cells integrated into his body.

The case, which is the first detailed report in a major academic journal of how doctors are using Crispr in living patients, is an "important milestone" and suggests that gene editing will be "a safe technology and that the challenge now is to have it be really effective in different disease settings", Ms Doudna noted. BLOOMBERG

Read the original:
Crispr's next frontier is in-human treatment, says co-inventor - The Business Times

Recommendation and review posted by Bethany Smith

A joint venture between gene-editing startup CRISPR Therapeutics and German pharmaceutical company Bayer will come under the control of CRISPR Therapeutics, according to the pairs proposed plans.

In an announcement published yesterday, October 21, CRISPR Therapeutics and Bayer proposed that the joint venture, Casebia Therapeutics, would focus on the development of its lead programmes in haemophilia, ophthalmology and autoimmune diseases.

The companies agreed to form Cambridge, Massachusetts-based Casebia Therapeutics in December 2015, with the aim of discovering, developing and commercialising new breakthrough therapeutics to cure blood disorders, blindness, and congenital heart diseases.

Samarth Kulkarni, CEO of CRISPR Therapeutics, said: As Casebia's programs have advanced beyond the discovery stage, we are evolving the operating model to leverage the manufacturing and clinical expertise of CRISPR Therapeutics to further accelerate these programmes.

Bayer will have opt-in rights for two products at investigational new drug application submissions.

Kemal Malik, Bayer board member for innovation, added: We remain excited about the potential of cutting-edge CRISPR/Cas9 based therapies, which have the potential to create a whole new class of medicines.

The transaction is expected to close in the fourth quarter of 2019.

In September, an alliance of companies that use gene-editing technologies (including CRISPR Therapeutics) released a bioethical framework, as controversy over gene-editing rages on.

The principles agree that the developers do not support germline gene editing (the process by which the genome of an individual is changed so that the change is heritable) in human clinical trials or for human implantation.

Last week, CRISPR Therapeutics announced that it had entered a licence agreement with biotech KSQ Therapeutics, gaining access to KSQs IP for editing certain novel gene targets in its allogeneic oncology cell therapy programmes.

KSQ gained access to CRISPR Therapeutics IP for editing novel gene targets identified by KSQ as part of its current and future cell programmes.

Did you enjoy reading this story?Sign up to our free newslettersand get stories like this sent straight to your inbox.

Bayer, CRISPR Therapeutics, joint venture, CRISPR, gene-editing, haemophilia, ophthalmology, autoimmune diseases

Read the original:
CRISPR Therapeutics to buy JV from Bayer - Life Sciences Intellectual Property Review

Recommendation and review posted by Bethany Smith

Russian scientist Denis Rebrikov recently revealed that he has started a gene-editing process that might eventually enable couples carrying the genetic mutation that causes deafness to give birth to children who can hear. The news was shared with Nature on 17 October via an e-mail.

According to Nature, the scientist mentioned in the e-mail that he will soon publish the results of his experiments, which involves testing the ability of CRISPR to repair the gene causing deafness GJB2 in cells taken from people that have the mutation. Rebrikov believes that the result will help to lay the groundwork for the clinical work. Rebrikov also added that he wants to help couples with unimpaired hearing to have a child such as these to have a child with the same mutation.

Rebrikov also mentioned that he has local review board's permission to do the research but it does not allow the transfer of the gene-edited eggs into the womb and pregnancy. The scientist also emphasized that he will not be going ahead without the approval from the Ministry of Health of the Russian Federation. "I will definitely not transfer an edited embryo without the permission of the regulator," he confirmed.

However, the chances of this happening seem to be really low as last week, the ministry released a statement where it mentioned that the production of gene-edited babies is premature. Rebrikov, however, is not ready to lose hope. He says, "it is hard to predict" when he'll get permission for it so till then all the necessary safety checks need to be undertaken.

Rebrikov has previously also announced that he intends to use the CRISPR tool for gene-edited babies resistant to HIV. At that time, the news came as a shock to all international researchers as people feared that he is following the Chinese scientist He Jiankui who previously announced the controversial birth of the world's first gene-edited babies twin girls.

See the original post:
CRISPR scientist wants to edit genes that cause deafness but falls short of permission - International Business Times, Singapore Edition

Recommendation and review posted by Bethany Smith

The CRISPR and CRISPR-associated (Cas) Genes market is anticipated to grow in the forecast, owing to the factors such as rising adoption of genome editing technique, growing adoption of CRISPR, and increasing prevalence of genetic disorders. Furthermore, increasing demand for drug discovery is likely to pose growth opportunities for the CRISPR and CRISPR-associated (Cas) Genes market to grow.

CRISPR & CRISPR-associated (Cas) Genes Market to 2027 Global Analysis and Forecasts By Product (Vector-based Cas, DNA-free Cas); Application (Genome Engineering, Disease models, Functional Genomics, Knockdown/activation, Others); End User (Biotechnology and Pharmaceutical Companies, Academic and Government Research Institutes, Contract Research Organizations) and Geography

CRISPR and CRISPR-Associated (Cas) Genes is a genome editing tool that enables the researchers to make changes in the DNA. CRISPR-Cas9 stands for clustered regularly interspaced short palindromic repeats and CRISPR-associated protein 9. In recent years the CRISPR and CRISPR-Associated (Cas) Genes has gained lot of popularity as it offers it is cheaper, faster, accurate, and more efficient genome editing methods.

Get PDF sample copy at https://www.theinsightpartners.com/sample/TIPRE00006876

What the report features:-

Leading key market players mentioned in the report:-

The Global CRISPR and CRISPR-associated (Cas) Genes market Analysis to 2027 is a specialized and in-depth study of the medical device industry with a special focus on the global market trend analysis. The report aims to provide an overview of CRISPR and CRISPR-associated (Cas) Genes market with detailed market segmentation by product, application, end user and geography. The global CRISPR and CRISPR-associated (Cas) Genes market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading CRISPR and CRISPR-associated (Cas) Genes market players and offers key trends and opportunities in the market.

The global CRISPR and CRISPR-associated (Cas) Genes market is segmented on the basis of product, application, and end user. Based on product the market is segmented into vector-based Cas and DNA-free Cas. Based on application the market is segmented into genome engineering, disease models, functional genomics, knockdown/activation and others. Based on end user the market is segmented into biotechnology and pharmaceutical companies, academic and government research institutes, contract research organizations.

Buy Complete Report at https://www.theinsightpartners.com/buy/TIPRE00006876

About Us

The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services.

We are committed to providing highest quality research and consulting services to our customers. We help our clients understand key market trends, identify opportunities, and make informed decisions by providing market research solutions at an affordable cost.

Contact us

The Insight partners,

Phone: +1-646-491-9876

Email: sales@theinsightpartners.com

Home: https://www.theinsightpartners.com

More:
2019 CRISPR & CRISPR-associated Genes Market to Emerge with Increasing Demand for Drug Discovery with Top Companies Insights - Thermo Fisher...

Recommendation and review posted by Bethany Smith

CRISPR Therapeutics AG (CRSP):

If you are considering getting into the day trading or penny stock market, its a legitimate and profitable method for making a living. Every good investor knows that in order to make money on any investment, you must first understand all aspects of it, so lets look at daily change, stock price movement in some particular time frame, volatility update, performance indicators and technical analysis and analyst rating. Picking a stock is very difficult job. There are many factors to consider before choosing a right stock to invest in it. If picking stock was easy, everyone would be rich right? This piece of financial article provides a short snap of CRISPR Therapeutics AG (CRSP) regarding Tuesday trading session and presents some other indicators that can help you to support yours research about CRISPR Therapeutics AG (CRSP).

CRISPR Therapeutics AG (CRSP) stock Trading Summary:

CRISPR Therapeutics AG (CRSP) stock changed position at -2.62% to closing price of $39 in recent trading session. The last closing price represents the price at which the last trade occurred. The last price is also the price on which most charts are based; the chart updates with each change of the last price. The stock registered Tuesday volume of 666406 shares. Daily volume is the number of shares that are traded during one trading day. High volume is an indication that a stock is actively traded, and low volume is an indication that a stock is less actively traded. Some stocks tend always to have high volume, as they are popular among day traders and investors alike. Other stocks tend always to have low volume, and arent of particular interest to short-term traders. The stock average trading capacity stands with 502.9K shares and relative volume is now at 1.33.

CRISPR Therapeutics AG (CRSP) Stock Price Movement in past 50 Days period and 52-Week period

CRISPR Therapeutics AG (CRSP) stock demonstrated 75.52% move opposition to 12-month low and unveiled a move of -27.64% versus to 12-month high. The recent trading activity has given its price a change of -22.68% to its 50 Day High and 9.98% move versus to its 50 Day Low. Prices of commodities, securities and stocks fluctuate frequently, recording highest and lowest figures at different points of time in the market. A figure recorded as the highest/lowest price of the security, bond or stock over the period of past 52 weeks is generally referred to as its 52-week high/ low. It is an important parameter for investors (as they compare the current trading price of the stocks and bonds to the highest/lowest prices they have reached in the past 52 weeks) in making investment decisions. It also plays an important role in determination of the predicted future prices of the stock.

CRISPR Therapeutics AG (CRSP) Stock Past Performance

CRISPR Therapeutics AG (CRSP) stock revealed -18.24% return for the recent month and disclosed -20.63% return in 3-month period. The stock grabbed 1.11% return over last 6-months and 8.21% return in yearly time period. To measure stock performance since start of the year, it resulted a change of 36.51%. Past performance shows you the funds track record, but do remember that past performance is not an indication of future performance. Read the historical performance of the stock critically and make sure to take into account both long- and short-term performance. Past performance is just one piece of the puzzle when evaluating investments. Understanding how performance fits in with your overall investing strategy and what else should be considered can keep you from developing tunnel vision.

Volatility in Focus:

The stock unfolded volatility at 4.71% during a week and it has been swapped around 5.62% over a month. Volatility is a rate at which the price of a security increases or decreases for a given set of returns. Volatility is measured by calculating the standard deviation of the annualized returns over a given period of time. It shows the range to which the price of a security may increase or decrease. Volatility measures the risk of a security. It is used in option pricing formula to gauge the fluctuations in the returns of the underlying assets. Volatility indicates the pricing behavior of the security and helps estimate the fluctuations that may happen in a short period of time. If the prices of a security fluctuate rapidly in a short time span, it is termed to have high volatility. If the prices of a security fluctuate slowly in a longer time span, it is termed to have low volatility.

The average true range is a volatility indicator. This stocks Average True Range (ATR) is currently standing at 2.06.

Overbought and Oversold levels

The stock has RSI reading of 43.34. RSI gives an indication of the impending reversals or reaction in price of a security. RSI moves in the range of 0 and 100. So an RSI of 0 means that the stock price has fallen in all of the 14 trading days. Similarly, an RSI of 100 means that the stock price has risen in all of the 14 trading days. In technical analysis, an RSI of above 70 is considered an overbought area while an RSI of less than 30 is considered as an oversold area. RSI can be used as a leading indicator as it normally tops and bottoms ahead of the market, thereby indicating an imminent correction in the price of a security. It is pertinent to note that the levels of 70 and 30 needs to be adjusted according to the inherent volatility of the security in question.

Analyst Watch: Analysts have assigned their consensus opinion on this stock with rating of 2.3 on scale of 1 to 5. 1 or 2 =>Buy view 4 or 5 => Sell opinion. 3 =>Hold. Analysts recommendations are the fountainhead of equity research reports and should be used in tangent with proprietary research and investment methodologies in order to make investment decisions.

Christopher Jones

Category Finance

Christopher Jones says that his huge experience in 5 years, gives him priority among others. He worked for different national and international companies. He has unique insights into the investments for oil and gas field. He likes to share his predictions and analysis with readers. He still creates profitable equity portfolios for his clients.

Christopher has worked as an auditor for many years but is currently working as a business journalist so that he can work remotely and travel with his wife while she works as a travel nurse for several years. Christopher specializes in stock, gas and oil investments, dividends. He is a well-known person in Finance world.

Address: 1646 Lone Mountain Road, O Brien, OR 97534 USA

Email: [emailprotected]

Zip code: 97534

Contact # 541-479-1890

Read more here:
Attractive Stock of Yesterday : CRISPR Therapeutics AG (CRSP) - WEB NEWS OBSERVER

Recommendation and review posted by Bethany Smith

On Monday, shares of CRISPR Therapeutics AG (NASDAQ:CRSP) marked $40.05 per share versus a previous $37.91 closing price. With having a 5.64% gain, an insight into the fundamental values of CRISPR Therapeutics AG, investors would also find a great ally in the technical patterns of the stock movements showed in stock charts. CRSP showed a rise of 40.18% within its YTD performance, with highs and lows between $22.22 $53.90 during the period of 52 weeks, compared to the simple moving average of -1.84% in the period of the last 200 days.

Jefferies equity researchers changed the status of CRISPR Therapeutics AG (NASDAQ: CRSP) shares to a Buy rating in the report published on August 1st, 2019. Other analysts, including Canaccord Genuity, also published their reports on CRSP shares. Canaccord Genuity repeated the rating from the previous report, marking CRSP under Buy rating, in the report published on July 26th, 2019. Additionally, CRSP shares got another Buy rating from ROTH Capital, setting a target price of $50 on the companys shares, according to the report published in June 10th, 2019. On the other hand, William Blair Initiated the Mkt Perform rating for CRSP shares, as published in the report on March 14th, 2019. Goldman seems to be going bullish on the price of CRSP shares, based on the price prediction for CRSP. Another Sell rating came from Citigroup.

The present dividend yield for CRSP owners is set at 0, marking the return investors will get regardless of the companys performance in the upcoming period. In addition, the growth of sales from quarter to quarter is recording -72.70%, hinting the companys progress in the upcoming progress.

In order to gain a clear insight on the performance of CRISPR Therapeutics AG (CRSP) as it may occur in the future, there are more than several well-rounded types of analysis and research techniques, while equity is most certainly one of the more important indicators into the companys growth and performance. In this case, you want to make sure that the return on the present equity of -51.50% is enough for you to make a profit out of your investment. You may also count in the quick ratio of the company, currently set at 14.00 so you would make sure that the company is able to cover the debts it may have, which can be easily seen in annual reports of the company.

Set to affect the volatility of a given stock, the average volume can also be a valuable indicator, while CRSP is currently recording an average of 496.33K in volumes. The volatility of the stock on monthly basis is set at 5.34%, while the weekly volatility levels are marked at 4.30%with 9.19% of gain in the last seven days. Additionally, long-term investors are predicting the target price of $62.13, indicating growth from the present price of $40.05, which can represent yet another valuable research and analysis points that can help you decide whether to invest in CRSP or pass.

CRISPR Therapeutics AG (CRSP) is based in the Switzerland and it represents one of the well-known company operating with Healthcare sector. If you wish to compare CRSP shares with other companies under Electronic Equipment and Consumer Goods, a factor to note is the P/E value of for CRISPR Therapeutics AG, while the value can represent an indicator in the future growth of the company in terms of investors expectations. The later value should have a steady growth rate, increasing and growing gradually, which serves the purpose of reliably showcasing the progress of the company. The value -3.93 is supported by the yearly ESP growth of -101.60%.

Besides from looking into the fundamentals, you should also note the number of people inside the company owning the shares, as the values should be in line with the expectations of investors. In that spirit, the present ownership of stocks inside the company is set at 2.00%, which can provide you with an insight of how involved executives are in owning shares of the company. In oppose to the executives share, the institutional ownership counts 51.10% of shares, carrying an equal significance as an indicator of value, as the presence of large investors may signal a strong company.

It appears that more than several institutional investors and hedge funds decided to increase stakes in CRSP in the recent period. That is how ARK Investment Management LLC now has an increase position in CRSP by 34.67% in the first quarter, owning 2.72 million shares of CRSP stocks, with the value of $111.67 million after the purchase of an additional 701,332 shares during the last quarter. In the meanwhile, Nikko Asset Management Americas, also increased their stake in CRSP shares changed 324.31% in the first quarter, which means that the company now owns 1.87 million shares of company, all valued at $76.71 million after the acquisition of additional 1,430,364 shares during the last quarter.

Waddell & Reed Investment Managem acquired a new position in CRISPR Therapeutics AG during the first quarter, with the value of $41.07 million, and Federated Global Investment Manag increased their stake in the companys shares by 8.82% in the first quarter, now owning 67,400 shares valued at $34.09 million after the acquisition of the additional 831663 shares during the last quarter. In the end, Bellevue Asset Management AG increased their position by during the first quarter, now owning 810462 CRSP shares, now holding the value of $33.22 million in CRSP with the purchase of the additional 810,462 shares during the period of the last quarter. At the present, 51.10% of CRSP shares are in the ownership of institutional investors.

Go here to read the rest:
At Current Price, Is It Too Late To Buy CRISPR Therapeutics AG (CRSP)? - US Post News

Recommendation and review posted by Bethany Smith

New Detection and Treatment for Cancer

According to the American Cancer Society, the oldest description of cancer dates back to Egypt around 3000 BC. Weve been looking for answers ever since. The good news is that there are new detection and treatments for cancer that are providing the way forward to earlier detection and more targeted therapy.

GRAIL, Inc. has a new blood test in development that screens for numerous types of cancer. Investigators at Dana-Farber Cancer Institute confirmed the test has an overall specificity of 99.4%. Results of the multi-center trial were presented at the European Society for Medical Oncology 2019 Congress on September 18, 2019.

By looking for DNA rather than liquid biopsies, the test is able to focus in on portions of the genome where abnormal methylation patterns are found in cancer cells. The lead author, Geoffrey Oxnard, MD of Dana-Farber, commented that if the test was in wide use, it would increase the number of patients who could receive more effective treatments.

Non-Opioid Chronic Pain Management

With the rise of awareness of the dangers of opioids, doctors and patients are turning to alternative solutions for chronic pain management. Physical therapy, acupuncture, surgery, injections, and nerve blocks are some of those solutions. However, for Richard Hanbury, the solution to his personal chronic pain would not be found in opioids but in the experimentation of relaxation techniques, pulsing lights, and sound. As he tracked the decrease of his own pain, he began to raise seed funding, and in 2018, with the help of Stanford University and the United States Special Operations Command, put the device to the test.

In January, the Smithsonian Magazine identified Hanbury, founder of Sana, as an innovator to watch in 2019. Sana has developed a non-invasive bio-therapeutic to manage chronic pain while reducing health care costs. The company has created a device that--with the push of a button--the combination of deep relaxation with the promotion of hemispheric balance leads to pain relief in 16 minutes. As of July of 2019, the company had completed the engineering and testing required for review for FDA approval. Pending FDA approval, it will first be available for fibromyalgia treatment. Additional clinical studies are underway for Opioid Use Disorder, Severe Pain, Neuropathic Pain, and Oncology Pain. The aim, says Hanbury, is to create less suffering and a better status of care.

Virtual Reality is also being used for pain management. VR provides a safe, effective, drug-free alternative in the aftermath of an opioid epidemic. Its even being used to monitor Alzheimer's disease.

AI Applications

Fast Company identified Arterys as one of the Worlds 50 Most Innovative Companies of 2019 for scanning smartly. With long waiting lists and a shortage of radiology specialists, Arterys saw a need for AI to help doctors quickly detect, measure, and track tumor and lesions in CT scans of the lungs and in MRI and CT scans of the liver. In August, a major French hospital signed a five-year deal to deploy the AI platform. The purpose is not to replace human radiologists, but to let the system do manual tasks, allowing the radiologist to focus more on the patient and the experience.

But Arterys isnt the only company providing AI assistance. Machines are being used to predict, comprehend, learn, and act. From surgery-assisting robots to faster diagnoses, AI has multiple applications in the life science industries. For more read 32 Examples of AI in Healthcare and Would You Trust An Automated Doctor?

Neurological Advancements

By 2050, the cost and diagnosis of neurological disorders is expected to nearly double. The good news is that innovation is happening at a rapid pace as scientists are discovering more about the function of the nervous system on molecular and genetic levels. According to an article in Americas Biopharmaceutical Companies, there are 537 medications currently being developed for the treatment of chronic pain, brain tumors, Alzheimers disease, Parkinsons disease, epilepsy, headaches, and migraines. The article highlights disease-modifying treatments for Alzheimers that have the potential to stop or slow down the progression of the disease.

According to Doug Williamson, chief medical officer and vice president of U.S. drug development at Lundbeck, hope is right around the horizon. Just as cancer has progressed from being a death sentence to often being treatable and in some cases curable, the next few decades will see far more effective treatments for a variety of neurological diseases.

It is not only in medication that we are seeing advancements for neurological diseases, like Alzheimers and Parkinsons disease. Earlier this year The Norman Fixel Institute for Neurological Diseases at the University of Florida Health in Gainesville opened its doors. Neurologists, neurosurgeons, neuropsychologists, physical therapists, occupational therapists, speech and swallowing specialists, nutritionists, psychiatrists and social workers are all working together under one roof, providing comprehensive and advanced care.

We are thinking broadly and establishing a coordinated approach to improvement of clinical care, drug discovery, as well as gene and neuromodulatory therapy, said David R. Nelson, M.D., senior vice president for health affairs at UF and president of UF Health. Our outstanding team of experts will continue to push the boundaries in identifying new, game-changing approaches to treating neurologic disease.

Direct to Consumer Hearing Aids

InnerScope Hearing Technologies Inc.(innd.com) received the Best Hearing Aid Manufacturer 2019 USA & GHP Award for its innovation in direct-to-consumer hearing aid delivery. The company is working to serve 1.2 billion people worldwide who have hearing loss by providing accessible and affordable solutions. There are five hearing aid manufacturers that control 97% of hearing aids sold globally. The company plans to disrupt this existing product with its patented self-fitting hearing aid that will be distributed through global big box retailers. InnerScope is also conducting a 510K FDA clinical trial on treatment for tinnitus. The goal is to provide quality care to people who previously have been unable to afford hearing devices.

2019/ 2020 Potential Jobs and Opportunities

As we finish out 2019 and enter 2020, the future of biotechnology and pharmaceuticals is promising. Innovations, small biotech startups, and clinical tests are advancing towards earlier diagnosis and more effective treatments. As more advances are made in the life sciences, additional opportunities will open. This is good news for those seeking employment, meaning its time to pitch your dream position into markets where they need you, but dont quite know why.You can check out current openings within the life sciences industry here.

Stay ahead of your competitors. Read Creating a Life Sciences Jobs Where One Doesnt Exist. Twenty years ago, would you have thought strapping on a headset would be an effective pain management strategy or that a cure for the HIV infection was possible? Go start tomorrow's innovations today. The future is waiting.

Continue reading here:
5 Biotech and Pharmaceutical Innovation Trends in 2019 - BioSpace

Recommendation and review posted by Bethany Smith

The touch of a feather, the itch of a mosquito bite, the prick of a needle: The body is capable of distinguishing and responding to all of these sensations in a near instantaneous relay, from skin to brain and back again.

Our brain is constantly computing these things, and in healthy people it never gets it wrong, says Ishmail Abdus-Saboor, a biologist in Penns School of Arts and Sciences.

The details that drive these processes are now at the heart of Abdus-Saboors research. Using a variety of techniques and models, he and his labestablished at Penn last yearseek to tease out the nervous system pathways involved in translating sensations to the brain, with a particular focus on acute and chronic pain.

His work has taken on a new significance in light of the opioid epidemic.

As a field we have really struggled in identifying novel pain killers, he says. This is why we have an overreliance on opioids.

Getting to the bottom of basic mechanisms in pain sensation has the potential to uncover new pathways that could be targeted with alternative medications. And with a new technique for applying a measurement to pain itself, Abdus-Saboor has in hand a platform that could be used to screen new drugs or even help clinicians one day evaluate their patients discomfort in a much more rigorous way than is currently available.

Animal behavior and biology got their hooks into Abdus-Saboor when he was a child. Growing up in Philadelphias Germantown neighborhood, he fashioned a laboratory in his home at age 14, winning a citywide science competition for his investigations of crayfish.

He carried that fascination with him through his undergrad years at North Carolina A&T State University, pursuing animal science as a pre-vet student. A summer in a laboratory at Penn refined that interest. The mysteries contained in the molecules and genes of animals began to emerge as the most captivating to Abdus-Saboor.

He wound up pursuing his graduate studies with Meera Sundaram at Penn in the Perelman School of Medicine, focusing on the genetics of the nematode worm Caenorhabditis elegans. But he made a conscious choice to shift gears as he embarked on two postdoctoral fellowships.

Thinking about running my own lab one day, I was considering which area has the biggest growth potential in biomedical research, he recalls. The brain is the last frontier; its the least well-understood organ. I thought that, if I could apply some of the tools that Id been learning in genetics and molecular biology toward the study of the nervous system, then perhaps I could make some important discoveries and look at things from a different vantage point.

First in a postdoctoral fellowship with Benjamin Shykind of Cornell University and in a second position working with Wenqin Luo back at Penn, Abdus-Saboor played catch up in the field of neuroscience.

Basically, every single approach that I worked on was new to me, he says. But I think that navet helped me.

Specifically, Abdus-Saboor started asking questions about the common techniques use to evaluate responses to sensory stimuli in mouse studies and wasnt satisfied with the answers. Certain assays, for example, relied on a binary responseeither the animals responded to a stimulus or they didnta measure that struck Abdus-Saboor as rather crude and possibly biased.

Over the last few years, as he wrapped up his postdoc with Luo and established his own lab at Penn, he set out to create a more refined scale for evaluating these types of responses. His technique relies on the use of a high-speed videography, capable of capturing 1,000 frames per second. In a paper published in August in Cell Reports, he, colleagueNathan Fried, Luo, and others reported the creation of a nuanced mouse pain scale that could effectively differentiate responses to a variety of sensory stimuli.

Taking lessons from other model systems, mainly fruit flies and zebrafish, people have been using high-speed cameras to slow down behaviors that we cant see with the naked eye, says Abdus-Saboor. I had the hypothesis that if we did this, maybe there was a lot more information we could extract that could inform us and teach us about what the animal is experiencing. And that turned out to be the case.

Processing frames from these recordings manually, which is how the researchers initially completed the study, was a tedious task. But working with biostatisticians, computational biologists, and machine-learning specialists, Abdus-Saboor and members of his lab were able to streamline the process, and, in collaboration with departmental colleague Joshua Plotkin, are working to automate the video frame-by-frame analysis.

We want others to easily adopt this technology, and automation would help avoid the potential error and variability of human scoring, he says. There are emerging technologies that are allowing us to do this.

So far, theyve tested the platform using both male and female mice representing a variety genetic types and have gotten consistent results across the board.

As his lab has developed this technology, theyve been working in parallel to more deeply understand the nervous system circuits that produce the sensation of pain, especially in the context of chronic pain. People who suffer from chronic pain become more sensitive to various types of touch, even an otherwise innocuous application of warmth or pressure.

This is the chronic pain we hear a lot about now, in this opioid epidemic era, Abdus-Saboor says.

In his relatively short time as a faculty member, hes already struck up collaborations with researchers working on pain elsewhere in the University to advance the science of treating pain. In the School of Dental Medicine, he and Claire Mitchell have worked together on a study of dental pain. Abdus-Saboor has also had productive conversations with researchers, such as Penn Dental Medicines Elliot Hersh, who are interested in applying his high-speed camera platform in clinical settings to objectively evaluate the patients pain and prescribe painkilling drugs appropriately.

Were not there yet, but these are conversations were starting to have, says Abdus-Saboor. If this technology could evolve into the clinic? That would be a wonderful thing.

Ishmail Abdus-Saboor is the Mitchell and Margo Blutt Presidential Assistant Professor in the Department of Biology at the University of Pennsylvanias School of Arts and Sciences.

Read the original:
The science of sensations - Penn: Office of University Communications

Recommendation and review posted by Bethany Smith

FOR many producers, the development of breed indexes was a significant step forward in the provision of genetic information.

As the number of EBVs increased with developments in performance recording, combined with new ways to capture genetic information, the complexity of making a purchase decision on a bull also became more challenging.

Breed Indexes offered an effective approach to considering the impact of genetic potential a bull possessed to influence the profitability of his progeny across the industry production chain. For many, this allowed a more focussed decision on bulls without having to individually assess each trait and attempt to consider how that would impact finishing traits of steers, or fertility traits in replacement heifers.

Although the Index was a strong guide, it allowed the opportunity for producers to create a short-list of potential bulls that could then be individually selected if required, based on personal preferences on specific genetic traits.

The development of Breed Indexes comes through world leading technology developed in Australia by AGBU the Australian Genetics Breeding Unit based in Armidale. BreedObject continues to refine and account for new genetic technologies and data, and with the release of Version 6, this has opened the possibility for breeds to reconsider the driving focus behind their breed indexes.

The first of the breed societies to reassess their indexes has been Herefords Australia.

Andrew Donoghue

Andrew Donoghue, the general manager of the Society, explained that the opportunity to provide Indexes that focussed on the production systems that Herefords were used within was an exciting outcome of the new BreedObject software.

We have been looking and talking with our members and across industry about where we as a breed want to head. Logically we know that the expectations for Herefords in Northern systems are very different to those in southern regions, Mr Donoghue said.

In the past the focus of the indexes was on finishing systems. However when we talk about finishing systems, the outcome is more about compliance with a specification effectively, hitting requirements for fatness, carcase weight and marbling.

So while some people choose to use grass finishing as their focus and others grain finishing, we are still effectively heading in the same direction.

As Mr Donoghue explained, the significant difference between production systems in the north and the south revolves largely around the cost of feed during annual feed gaps.

The cost of feed in those periods is significant depending where the cattle are located, he said, and this has a major impact on a production systems profitability.

Choosing bulls that can have a genetic influence on a herds feed efficiency, as well as growth and mature weights will help producers adjust their programs to better meet their environmental constraints in a profitable way, he said.

Click on image for a larger view

For producers, the change in Indexes will be to step away from looking at a finishing system, and ranking bulls according to their value.

Instead, the first step will be to consider their location as either a southern or northern producer. From there, the progression is to select a production system that reflects their operation, before then choosing the most suitable bulls for that program.

The Hereford Indexes to be released this month have all been developed with a focus on maintaining and improving eating quality outcomes. Within the model that creates the ranking, premiums to reflect marbling were included, as well as placing pressure on early growth in order to maintain low levels of ossification.

Once producers have chosen their location and production system, there are four indexes that can be considered. For those in southern production regions these will be:

Andrew Donoghue highlighted the major difference between the Northern and Southern Self-Replacing Index as being a significant difference in feed cost.

While the Index still targets the production of cattle for the domestic market, he said it was envisaged that producers would use this in either straightbred Hereford herds or where Hereford bulls are going into crossbred herds, say over a Bos indicus composite based cow herd.

Finishing weights are slightly higher in the northern systems and the indexes also pick this up in the calculations, he said.

The second Northern focused Index, the Northern Baldy Terminal Index is one that will appeal to producers who are choosing Hereford Bulls to join to Bos indicus infused females (eg Santa Gertrudis) where all progeny (male and female) are destined for slaughter. The finishing systems are calculated with steers and heifers slaughtered at 18-19 months of age; steers producing 340kg carcases with 14mm of P8 fat depth, and heifers producing 300kg carcases with 17mm of P8 fat.

In discussing the new Indexes, Mr Donoghue highlighted the attention focussed on creating a system that more realistically reflects production, and environmental pressures experienced by breeders across the country.

We have really spent a lot of time consulting with our members and across industry ensuring that the new indexes align with the key production and market systems for Hereford cattle, he said.

Alastair Rayner

Alastair Rayner is the Principal of RaynerAg, an agricultural advisory service based in NSW. He regularly attends bull sales to support client purchases and undertakes pre sale selections and classifications. He can be contacted here or through his website http://www.raynerag.com.au

Visit link:
Weekly genetics review: Production systems the focus in new breed indexes - Beef Central

Recommendation and review posted by Bethany Smith

HEREDITY, AS well as medical conditions and some medications and supplements, are all common causes of hair loss in men. When determining the key cause of baldness, it is important to understand ones personal genetics and account for any other risk factors and practices that may damage the hair.

We lose approximately 100 hairs a day, a loss that does not cause noticeable bald spots. However, when this loss is aggravated, a baldness pattern will appear or the hair will start falling noticeably more than usual. Some of the common causes include the following:

While genetic baldness is not preventable, you can reduce or mitigate other risk factors by talking to your physician when you start a new medical treatment that lists hair loss among its side effects.

Some of the above mentioned causes may have easy fixes, such as implementing a healthy and balanced diet that will include lots of proteins, iron, and zinc. Removing the causes of stress and paying attention to how you style your hair is also important. You may want to stop using damaging hair products or keeping your hair in a too-tight bun, for those who prefer the man bun.

Identifying the cause of hair loss is the first step towards treating the problem. Once you have determined it, you can talk to a physician. He may recommend hair prescription tablets or a hair transplant as a suitable solution for the genetic causes of hair loss.

Continue reading here:
Common causes of hair loss in men - The Voice Online

Recommendation and review posted by Bethany Smith

Everyone handles their mental health in different ways. Some people turn to the gym for stress release and waves ofendorphins. There are people who turn to meditation, mindfulness, spirituality and religion for peace of mind and body. Therapy is another way people find clarity and control over their demons. There are people who take medication to help treat their mental illness, and people who do one or more of the above. Whatever path you choose to find healing is your decision, and it is no one elses job to judge your path. We are all different people and therefore need different things. Healing is not a one-size-fits-all deal, and we should all be encouraged to find what helps us.

I began my healing in 2013 when I first graduated high school and was off to college. I always knew I had depression, but I never saw it for the monster it was. I had been in therapy since I was about 8 years old due to my parents divorce and I felt like I was doing fine. I went to college in the fall and started to experience extreme panic attacks and fell into a deep depression. I dropped out a month later and moved home to solve this hiccup in my path. A few appointments later, I found my way to a new doctor (since I was too old for my pediatrician) and was put on antidepressants for my depression. This continued until 2016 when I found a new physician, since mine was getting me nowhere, and decided to find an adult therapist. I was put on three different medications, went to intensive therapy on and off and found myself at college graduation three years later. Honestly? I was proud I made it that far because during that time I was drowning. I was taking medicine, working out every day, going to therapy but why wasnt I better?

Related: Review: Paul Rudds New Netflix Show 'Living With Yourself' Captures What Its Like to Be Split by Depression

I moved home and began the search for a full-time job. The transition to adulthood is hard and it is very real. My anxiety and depression were still there in full swing, but I was able to get through a few months without a total meltdown. After weeks of interviews, I was offered a job; and two weeks into it, I quit. I spiraled right back into the deep end and immediately ran to my general doctor for a medication change. A year went by, I thought I solved it and was offered a similar position to the one before. Two days after accepting the job offer, I spiraled into a manic episode and crashed. I started my new job and shortly after, almost landed myself in the hospital from violent panic attacks. I quit. I had to start all over, where was I even supposed to begin?

This was me August of 2019. This was me two months ago. In those two months, I have found more answers than I ever have before. Do you want to know how?

Related: How I'm Learning Not to Fear Recovery From Depression

I found a professional in the field.

Not a general doctor.

Not a family therapist.

But rather a psychiatrist who specializes in treating mental illness day in and day out. A therapist who met me where I was and continues to challenge me in ways I can understand.

I share this story because mental illness is no joke. It is not fake, it is not something that people make up. It is real and it is raw. My brain is sick and I had spent the last six years searching for answers from people who were not qualified to give me any. It is vital to find someone who specializes in what you are searching for. Do you want to know how I know?

My psychiatrist spent my first appointment talking to me about my life, then ran a DNA test to see what medications would work with my genetics. It turns out, the five different medications I tried and was rotated on did not work for my genetics. Not one. Chemically, they were not a match. I spent six years spending money and searching for answers in people who did not have the background to help me.

Related: 4 Tips That Help Me Complete Simple Tasks When I'm Depressed

If you want to change your medication, or start taking it, find someone who specializes in it. If you want to start working out and dont know where to start, find a trainer at a nearby gym. If you want to learn meditation, find a class or research it. If you want to delve deeper into spirituality, find a spiritual guide to help you.

Follow this link:
What Happened When I Found the Right Doctor for My Depression - Yahoo Lifestyle

Recommendation and review posted by Bethany Smith

Adrienne Moore knew something was wrong. After being diagnosed and successfully treated for ovarian cancer a decade earlier, she recognized the pain and bleeding she began to experience during intercourse, and the sudden irregularity of her periods, as signs of a potentially serious problem with her reproductive health.

Moore, a 45-year-old respiratory nurse from Atlanta, was terrified that her cancer had returned. But when she sought help from her doctors in 2012, she left her appointments with a series of misdiagnoses: perimenopause, cysts, fibroids. Being in the medical world, I thought I knew how to communicate with my caregivers, she says. But even as she pressed her fears, it felt like no one was listening.

She returned to her doctors repeatedly over the next three years, but her symptoms didnt improve. When her employers switched her health insurance plan, and her monthly premium jumped, Moore became unable to afford specialist care. As the pain grew unbearable, she requested sick leave from work. Instead, she was laid off. Her family paid out of pocket for scans and tests that Moore herself ordered. Still, doctors found nothing wrong.

But growing in Moores pelvic cavity, across her ovaries and into the endometriumthe lining of her wombwas a disease that could kill her.

Endometrial cancer is the most common type of gynecological cancer in the United States. Four times more common than cervical cancer, and the fourth most common cancer in women, its one of the few cancers in the country for which diagnoses and deaths are on the rise. The American Cancer Society estimates that at least 57,000 women will be diagnosed this year, and more than 11,000 will die.

Black women are just as likely to get endometrial cancer as white women, but they are more likely to die from it. Within every age, within every stage of diagnosis, within every tumor type, black women do worse, says Dr. Kemi Doll, a gynecologic oncologist at the University of Washington.

Doll has spent the past seven years researching gynecological cancers and investigating the cause of the disparity. She believes that, as with racial discrepancies in other medical conditions, the difference in the endometrial cancer death rate is the result of how the medical establishment treats black women.

To start, black women are less likely than white women to receive an early diagnosis for the disease. As a result, thousands discover they have the cancer only after it has spread, when they have less chance of survival.

That could be because doctors miss early signs of the disease, or because many black women are more reluctant or less able than their white counterparts to seek help from doctors. For many black women, confidence in the health care system has been undermined by decades of difficult experiences. Studies have found that doctors are more likely to view black patients as medically uncooperative, and that diagnostic and treatment decisions are influenced by patients race. Black patients consistently report higher levels of dissatisfaction with their care and mistrust of their doctors. Doll says that patients she speaks with frequently describe feeling dismissed, ignored, or overwhelmed. If you consider a black woman in the US who has had a lifetime of experiences of subpar reproductive health care, Doll says, it might not be that a couple of drops of postmenopausal bleeding has you running to the doctor.

And even those, like Moore, who seek help early for endometrial cancer receive less aggressive care. A recent study conducted by Dolls team found that black women with health insurance or access to medical care were less likely than white women to receive biopsies that could confirm their cancer earlier. Another found that 40 percent of the black-white mortality gap in endometrial cancer may be due to inequitable surgery rates: research shows that black women are less likely to receive surgery than white women at every stage of the disease, and they are also less likely to receive chemotherapy.

For further proof, Doll points to the racial discrepancies that exist in other diseases. Black women are less likely than white women to be tested for hereditary genetic mutations linked to breast cancer. Black patients with end-stage renal disease are less likely to be considered appropriate candidates for kidney transplants. Compared with white patients, black patients are more likely to die from breast, prostate, and stomach cancer, more likely to develop Alzheimers, and more likely to have a stroke. When it comes to maternal care, black women are almost four times more likely to die a pregnancy-related death than white women, and more likely to experience pregnancy complications like preeclampsia, placental abruptions, and postpartum hemorrhage.

You can either approach it from the standpoint that there is something fundamentally wrong with black womens bodies, or theres something wrong with the way we treat black women and their bodies, Doll says. We are not going to help women, and we are not going to solve this problem, if we dont deal with the problem of race and racism.

Not everyone agrees entirely with Dolls prognosis. Dr. Rodney Rocconi, interim director of the University of South Alabama Mitchell Cancer Institute, believes that biology plays an important part in endometrial cancers mortality disparity. Rocconi points to the fact that black women are more likely to be diagnosed with an aggressive form of endometrial cancer, regardless of how early she is diagnosed.

Rocconis research has found that women with a higher percentage of African ancestry are significantly more likely to have a genetic mutation that allows tumors to grow unchecked. Other research corroborates this idea: certain genetic mechanisms that help suppress tumors are less active in black women. Studies of kidney disease and hypertension suggest that genetics may also play part in increasing black peoples risk of developing the illnesses.

Critics argue that research linking race, genetics, and disease veers troublingly close to endorsing theories of eugenics and promoting pseudo-scientific racism. Rocconi agrees that theres no such thing as a black gene. But identifying a concrete link between black womens genetics and the aggressive tumors they suffer could be the first step in finding a cure. Whats most exciting to me is that we can target the biological cause of the disease, Rocconi says. Once the research is confirmed, we can add a targeted therapy to inhibit that immune pathway, and make patients more likely to respond to therapy.

But progress is hampered by another racial discrepancy, this time in clinical trials. Black enrollment numbers for early-phase endometrial cancer clinical trials, Rocconi notes, are dismal: For even one white person enrolled, 0.04 black people are. That first phase in clinical trials helps set the pipeline for agents that can be used in patients, Rocconi says. We are self-selecting [therapies] that work in the majority white population. This is a widespread problem. A recent ProPublica investigation found that in trials for 18 drugs targeting cancers that occur at least as frequently in black people as white, on average only 4.1 percent of participants were black.

To increase participation, Rocconi says, doctors must find a way to garner black patients trust in medical institutions. In Alabama, where the infamous Tuskegee syphilis experiment remains in living memory, Rocconi has had success enrolling more black patients in cancer treatment trials thanks to a University of South Alabama peer support program that helps patients understand treatment plans and medications and access things like medical insurance, hospital transportation, and community services. These were black women who were talking to people from the same community, Rocconi says. They were advocates for them.

Rocconis and Dolls research converge in another way, too: Both researchers believe epigenetics, the idea that social, economic, and cultural inequalities can alter our DNA, might also have a role in explaining why more black women are dying from endometrial cancer. Since the inequalities black women face persist throughout lifetimes, the resulting epigenetic changes keep accumulatingresulting in poorer health outcomes, including cancer, among certain racial and ethnic groups, a study co-written by Rocconi asserts. In other words, black womens genes may predispose them to aggressive endometrial cancer. But those genes have been influenced by generations of inequality.

This is why Doll believes that her patients experiences are key. The genetic information that youre getting comes from a person who had an experience, she says. And if you dont look at that experience you simply wont ever know how it may be influencing what youre seeing on the genetic level.

Back in Atlanta, Adrienne Moore was determined to find answers to what was ailing her. When she started a new job, a year after being laid off, she used her reinstated health benefits to order a biopsy on one of her cysts. It confirmed what she thought she already knew: She had cancer. But when the oncologist described the disease, she was shocked. She had never heard of endometrial cancer before. Her disease was so advanced, she was diagnosed at Stage 3. She was lucky to survive.

As she finished chemotherapy, Moore joined the Endometrial Cancer Action Network for African-Americans, a national support group founded by Doll. The organization hosts an online community for survivors and an education arm that informs black women about the disease, and its members serve as a research pool for ongoing studies into the cancers causes and treatments. Moore, whose cancer is now in remission, is a patient advisor for ECANA and conducts outreach to black women across Georgia.

Theres such a silence around our reproductive health, says Moore. She feels she had a lucky escape. When black women tell me theyve never heard of endometrial cancer, she says, its probably because weve lost so many to this disease.

See the article here:
Why Are More Black Women Dying From the Most Common Reproductive Cancer? - Mother Jones

Recommendation and review posted by Bethany Smith

Oct. 21, 2019 05:00 UTC

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the Phase III IMbrave150 study, evaluating Tecentriq (atezolizumab) in combination with Avastin (bevacizumab) as a treatment for people with unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy, met both of its co-primary endpoints demonstrating statistically significant and clinically meaningful improvements in overall survival (OS) and progression-free survival (PFS) compared with standard-of-care sorafenib.

Safety for the combination of Tecentriq and Avastin was consistent with the known safety profiles of the individual medicines, with no new safety signals identified. Data from the IMbrave150 study will be presented at an upcoming medical meeting.

We are very pleased with the results of our study testing the combination of Tecentriq and Avastin, which marks the first treatment in more than a decade to improve overall survival in people with unresectable hepatocellular carcinoma who have not received prior systemic therapy, said Levi Garraway, M.D., Ph.D., chief medical officer and head of Global Product Development. HCC is a major cause of death globally and particularly in Asia, making this study an important step in our mission of addressing unmet medical needs for patients around the world. We will submit these data to global health authorities as soon as possible. Our hope is to bring a new treatment to people with this aggressive disease who currently have limited options.

In July 2018, the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation (BTD) for Tecentriq in combination with Avastin in HCC based on data from an ongoing Phase Ib trial.

Genentech has an extensive development program for Tecentriq, including multiple ongoing and planned Phase III studies, across lung, genitourinary, skin, breast, gastrointestinal, gynecological and head and neck cancers. This includes studies evaluating Tecentriq both alone and in combination with other medicines.

About the IMbrave150 study

IMbrave150 is a global Phase III, multicenter, open-label study of 501 people with unresectable HCC who have not received prior systemic therapy. People were randomized 2:1 to receive the combination of Tecentriq and Avastin or sorafenib. Tecentriq was administered intravenously, 1200 mg on day 1 of each 21-day cycle, and Avastin was administered intravenously, 15 mg/kg on day 1 of each 21-day cycle. Sorafenib was administered by mouth, 400 mg twice per day, on days 1-21 of each 21-day cycle. People received the combination or the control arm treatment until unacceptable toxicity or loss of clinical benefit as determined by the investigator. Co-primary endpoints were OS and PFS by independent review facility (IRF) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1). Secondary efficacy endpoints included overall response rate (ORR), time to progression (TTP) and duration of response (DoR), as measured by RECIST v1.1 (investigator-assessed [INV] and IRF) and HCC mRECIST (IRF), as well as patient-reported outcomes (PROs), safety and pharmacokinetics.

About hepatocellular carcinoma

According to the American Cancer Society, it is estimated that more than 42,000 Americans will be diagnosed with liver cancer in 2019. Liver cancer incidence has more than tripled since 1980 and HCC accounts for approximately 75% of all liver cancer cases in the United States. HCC develops predominantly in people with cirrhosis due to chronic hepatitis (B and C) or alcohol consumption, and typically presents at an advanced stage where there are limited treatment options.

About the Tecentriq and Avastin combination

There is a strong scientific rationale to support further investigation of Tecentriq plus Avastin in combination. Avastin, in addition to its anti-angiogenic effects, may further enhance Tecentriqs ability to restore anti-cancer immunity by inhibiting vascular endothelial growth factor (VEGF)-related immunosuppression, promoting T-cell tumor infiltration and enabling priming and activation of T-cell responses against tumor antigens.

About Tecentriq (atezolizumab)

Tecentriq is a monoclonal antibody designed to bind with a protein called PD-L1. Tecentriq is designed to bind to PD-L1 expressed on tumor cells and tumor-infiltrating immune cells, blocking its interactions with both PD-1 and B7.1 receptors. By inhibiting PD-L1, Tecentriq may enable the re-activation of T cells. Tecentriq may also affect normal cells.

About Avastin (bevacizumab)

Avastin is a prescription-only medicine that is a solution for intravenous infusion. It is a biologic antibody designed to specifically bind to a protein called VEGF that plays an important role throughout the lifecycle of the tumor to develop and maintain blood vessels, a process known as angiogenesis. Avastin is designed to interfere with the tumor blood supply by directly binding to the VEGF protein to prevent interactions with receptors on blood vessel cells. The tumor blood supply is thought to be critical to a tumors ability to grow and spread in the body (metastasize).

Tecentriq U.S. Indications

Tecentriq is a prescription medicine used to treat adults with:

A type of bladder and urinary tract cancer called urothelial carcinoma. Tecentriq may be used when your bladder cancer:

The approval of Tecentriq in these patients is based on a study that measured response rate and duration of response. Continued approval for this use may depend on the results of an ongoing study to confirm benefit.

A type of lung cancer called non-small cell lung cancer (NSCLC).

A type of breast cancer called triple-negative breast cancer (TNBC).

Tecentriq may be used with the medicine paclitaxel protein-bound when your breast cancer:

The approval of Tecentriq in these patients is based on a study that measured the amount of time until patients disease worsened. Continued approval for this use may depend on results of an ongoing study to confirm benefit.

A type of lung cancer called small cell lung cancer (SCLC).

It is not known if Tecentriq is safe and effective in children.

Important Safety Information

What is the most important information about Tecentriq?

Tecentriq can cause the immune system to attack normal organs and tissues and can affect the way they work. These problems can sometimes become serious or life threatening and can lead to death.

Patients should call or see their healthcare provider right away if they get any symptoms of the following problems or these symptoms get worse.

Tecentriq can cause serious side effects, including:

Getting medical treatment right away may help keep these problems from becoming more serious. A healthcare provider may treat patients with corticosteroid or hormone replacement medicines. A healthcare provider may delay or completely stop treatment with Tecentriq if patients have severe side effects.

Before receiving Tecentriq, patients should tell their healthcare provider about all of their medical conditions, including if they:

Patients should tell their healthcare provider about all the medicines they take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

The most common side effects of Tecentriq when used alone include:

The most common side effects of Tecentriq when used in lung cancer with other anti-cancer medicines include:

The most common side effects of Tecentriq when used in triple-negative breast cancer with paclitaxel protein-bound include:

Tecentriq may cause fertility problems in females, which may affect the ability to have children. Patients should talk to their healthcare provider if they have concerns about fertility.

These are not all the possible side effects of Tecentriq. Patients should ask their healthcare provider or pharmacist for more information. Patients should call their doctor for medical advice about side effects.

Report side effects to the FDA at 1-800-FDA-1088 or http://www.fda.gov/medwatch.

Report side effects to Genentech at 1-888-835-2555.

Please visit http://www.Tecentriq.com for the Tecentriq full Prescribing Information for additional Important Safety Information.

Avastin is approved for:

Avastin in combination with paclitaxel, pegylated liposomal doxorubicin or topotecan, is approved to treat platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer (prOC) in women who received no more than two prior chemotherapy treatments.

Avastin, either in combination with carboplatin and paclitaxel or with carboplatin and gemcitabine, followed by Avastin alone, is approved for the treatment of patients with platinum-sensitive recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer (psOC)

Possible serious side effects

Everyone reacts differently to Avastin therapy. So, its important to know what the side effects are. Although some people may have a life-threatening side effect, most do not. Their doctor will stop treatment if any serious side effects occur. Patients should contact their health care team if there are any signs of these side effects.

Side effects seen most often

In clinical studies across different types of cancer, some patients experienced the following side effects:

Avastin is not for everyone

Patients should talk to their doctor if they are:

Patients should talk with their doctor if they have any questions about their condition or treatment.

Report side effects to the FDA at 1-800-FDA-1088 or http://www.fda.gov/medwatch.

Report side effects to Genentech at 1-888-835-2555.

For full Prescribing Information and Boxed WARNINGS on Avastin please visit http://www.avastin.com.

About Genentech in personalized cancer immunotherapy

For more than 30 years, Genentech has been developing medicines with the goal to redefine treatment in oncology. Today, were investing more than ever to bring personalized cancer immunotherapy (PCI) to people with cancer. The goal of PCI is to provide each person with a treatment tailored to harness his or her own immune system to fight cancer. Genentech is currently studying more than 10 cancer immunotherapy medicines across 70 clinical trials alone or in combination with other medicines. In every study we are evaluating biomarkers to identify which people may be appropriate candidates for our medicines. For more information visit http://www.gene.com/cancer-immunotherapy.

About Genentech

Founded more than 40 years ago, Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with serious and life-threatening medical conditions. The company, a member of the Roche Group, has headquarters in South San Francisco, California. For additional information about the company, please visit http://www.gene.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20191020005095/en/

See original here:
Genentech's Tecentriq in Combination With Avastin Increased Overall Survival and Progression-free Survival in People With Unresectable Hepatocellular...

Recommendation and review posted by Bethany Smith

T-levels boosters and sexual performance enhancers usually come at a steep price and you dont even have the guarantee that theyll render good results. The Krygen XL proves that you can have both potent ingredients, and a fair price for reaching your athletic and personal objectives.

This highly anticipated product is formulated with pharmaceutical-grade pro-sexual ingredients, that will boost your sex life into top gear.

The Krygen XLs new and improved formula helps rev your sexual system into its top shape, by helping you achieve harder erections, ramping up your stamina and power in bed, and helping you perform at your peak.

Men with higher levels of the male hormone usually have greater sexual activity. Older men need to secrete more of it for their libido and erectile function to work properly.

Visit the official website and get your hands on the first bottle of the Krygen XL sent out to you for FREE anywhere in the UK!

But its important to note that erectile dysfunction is often due to other conditions or medications rather than low testosterone levels.

Studies show that testosterone therapy can benefit your sexual health and performance. It also shows that there is a maximum level of testosterone before theres no increased response. For men who dont have hypogonadism, increasing your testosterone may not benefit your libido.

So, boiling it down to the basic benefits, The Krygen XL will:

So a formula that makes all of those things possible has become the core interest of the scientific world. This is where the Krygen XL came into play and due to its rapid absorption technology and fast-acting, all-natural formula, it delivers a blend of ingredients that help boost the flow of blood to the penis chambers and expands its holding capacity.

Regular use of the supplement has a positive effect on the size of your male parts, helping you amp up your manhood, both in terms of length and girth.

Krygen XLs extra strength blend helps maximize the attributes mentioned earlier to help you experience a complete transformation of your sexual health, performance, & confidence.

Why choose the Krygen XL and not another testo enhancer?

Disclaimer:

For more information about the Krygen XL offer please visit the official website.

See original here:
Krygen XL has now become the best priced and best reviewed male enhancement supplement in the UK - I'm Herald

Recommendation and review posted by Bethany Smith

HTF MI recently introduced study Global Testosterone Replacement Therapy Market Research Report 2019 with in-depth focused approach on qualitative research, describing product Scope and elaborating industry insights and outlook to 2022. The market Study is putting a lot of emphasis on macro-economic issues, influencing factors and key market trends and drivers gearing up and are changing the dynamics of Global Testosterone Replacement Therapy market.

Access Sample Copy @: https://www.htfmarketreport.com/sample-report/1620908-global-testosterone-replacement-therapy-market-11

TheGlobal Testosterone Replacement Therapy Market research studyis designed especially for business strategists, industry executives, marketing, sales and product managers & consultants highlighting the value drivers that may provides a competitive advantage to a business, giving an upper hand in the industry. What differentiation strategist should bring in its product or services understanding the competitors move and consumer behavior to make it more appealing? The report offers a measurable and verifiable method with in-depth analysis of market concentration, new entrants and the technological advancement and market trends in future. Some of the key vendors driving the market are AbbVie, Endo International, Eli lilly, Pfizer, Actavis (Allergan), Bayer, Novartis, Teva, Mylan, Upsher-Smith, Ferring Pharmaceuticals, Kyowa Kirin & Acerus Pharmaceuticals.

Testosterone deficiency, also referred to as hypogonadism, is a common problem among men aged between 40 and 79 years, with some studies stating that nearly 30% of all men worldwide are affected by hypogonadism. As the incidence of testosterone deficiency increases, it is expected that the demand for TRT will also show a simultaneous increase.The global average price of testosterone replacement therapy is in the decreasing trend, from 45.4 USD/Unit in 2012 to 34.9 USD/Unit in 2016. With the situation of global economy, prices will be in decreasing trend in the following five years.The classification of testosterone replacement therapy includes gels, injections, patches and other types, and the proportion of gels in 2016 is about 72%.Testosterone replacement therapy is widely sold in hospitals, clinics and other field. The most proportion of testosterone replacement therapy is sold in clinics, and the consumption proportion is about 43%.North America region is the largest supplier of testosterone replacement therapy, with a production market share nearly 86% in 2016. Europe is the second largest supplier of Testosterone Replacement Therapy, enjoying production market share nearly 9.9% in 2016.North America is the largest consumption place, with a consumption market share nearly 83% in 2016. Following North America, Europe is the second largest consumption place with the consumption market share of 12%. Market competition is intense. AbbVie, Endo International, Eli Lilly, Pfizer, Actavis (Allergan)Bayer, etc. are the leaders of the industry. The top five players together held about 80% of the market in the same year and they hold key technologies and patents, with high-end customers; have been formed in the monopoly position in the industry. The global Testosterone Replacement Therapy market is valued at 1820 million US$ in 2018 is expected to reach 1300 million US$ by the end of 2025, growing at a CAGR of -4.1% during 2019-2025. This report focuses on Testosterone Replacement Therapy volume and value at global level, regional level and company level. From a global perspective, this report represents overall Testosterone Replacement Therapy market size by analyzing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan. At company level, this report focuses on the production capacity, ex-factory price, revenue and market share for each manufacturer

Buy this research report@https://www.htfmarketreport.com/buy-now?format=1&report=1620908

Further to get in-depth view of Market competitive landscape and Size, The Global Testosterone Replacement Therapy market study is segmented by Application/ end users [Hospitals, Clinics & Others], products type [, Gels, Injections, Patches & Other]. Geographically, this report study is segmented into several key Regions such as North America, Europe, China & Japan with revenue, value drivers and growth rate of Testosterone Replacement Therapy to achieve a competitive edge, value proposition and market dominance in lucrative regions across the globe.

Some of the key questions answered in this report: Detailed Overview of Testosterone Replacement Therapy market will help deliver clients and businesses making strategies. Influencing factors that thriving demand and latest trend running in the market What is the market concentration? Is it fragmented or highly concentrated? What trends, challenges and barriers will impact the development and sizing of Global Testosterone Replacement Therapy market SWOT Analysis of each defined key players along with its profile and Porters five forces tool mechanism to compliment the same. What growth momentum or acceleration market carries during the forecast period? Which region may tap highest market share in coming era? Which application/end-user category or Product Type may seek incremental growth prospects? What would be the market share of key countries likeUnited States, France, Germany, UK, China, and Australia & Japan etc.? What focused approach and constraints are holding the Testosterone Replacement Therapy market tight?

Make Inquiry before purchase @https://www.htfmarketreport.com/enquiry-before-buy/1620908-global-testosterone-replacement-therapy-market-11

Chapter 1 is related to Executive summary to describe Definition, Specifications and Classification of Global Testosterone Replacement Therapy market, Applications such as Hospitals, Clinics & Others, Market Segment by Regions;Chapter 2, about objective of the report.Chapter 3, to display Research Methodology used for the report, Comprehensive analysis, using market research tools such as Porters and SWOT analysisChapter 4 , to show the Overall Market Analysis, segmentation analysis, characteristics;Chapter 5, 6 and 7, to show the Market size, share and forecast; Five forces analysis (bargaining Power of buyers/suppliers), Threats to new entrants and market condition;Chapter 8 and 9, to show analysis by regional segmentation North America, Europe, China & Japan, comparison, leading countries and opportunities; Regional Marketing Type Analysis, Supply Chain Analysis.Chapter 10, focus on identifying the key industry influencers, consumer behavior, marketing channels, Industry experts and strategic decision makers overview;Chapter 11 and 12, Market Trend Analysis, Drivers, Challenges by consumer behavior and demand.Chapter 13 and 14, describe about the vendor landscape (classification and Market Positioning)Chapter 15, deals with Testosterone Replacement Therapy Market sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source.

Early buyers will receive 10% customization in this research study. Read Detailed Index of full Research Study at @https://www.htfmarketreport.com/reports/1620908-global-testosterone-replacement-therapy-market-11

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.

About Author:HTF Market Report is a wholly owned brand of HTF market Intelligence Consulting Private Limited. HTF Market Report global research and market intelligence consulting organization is uniquely positioned to not only identify growth opportunities but to also empower and inspire you to create visionary growth strategies for futures, enabled by our extraordinary depth and breadth of thought leadership, research, tools, events and experience that assist you for making goals into a reality. Our understanding of the interplay between industry convergence, Mega Trends, technologies and market trends provides our clients with new business models and expansion opportunities. We are focused on identifying the Accurate Forecast in every industry we cover so our clients can reap the benefits of being early market entrants and can accomplish their Goals & Objectives.Contact US :Craig Francis (PR & Marketing Manager)HTF Market Intelligence Consulting Private LimitedUnit No. 429, Parsonage Road Edison, NJNew Jersey USA 08837Phone: +1 (206) 317 1218sales@htfmarketreport.comConnect with us atLinkedIn|Facebook|Twitter

Follow this link:
Testosterone Replacement Therapy Market Growing Demand, Analysis by Key Players-Bayer, Novartis - The Market Journal

Recommendation and review posted by Bethany Smith

10/22/2019

ABERDEEN - In a first for the sector, industry bodies Subsea UK and the Umbilical Manufacturers Federation have joined forces to deliver a conference focusing on the new developments and opportunities which exist in the subsea umbilicals industry.

The global subsea umbilicals, risers and flowline market is forecast to be worth more than 5billion by 2021 and the half-day conference, which will take place on Thursday, 21 November at the Chester Hotel in Aberdeen, will focus on the opportunities which exist in the growing sector. Ahead of the conference, a networking reception will take place at the hotel the night before (Wednesday 20 November).

A number of experts, including representatives from oil and gas super-majors and service companies will explore a range of topics relating to subsea umbilicals including project achievements to date, life extension and safety. Shell, Equinor, Subsea 7, Aker Solutions, Oceaneering, JDR Cable Systems, Fibron, Nexans, MAATS Tech and Trelleborg will all deliver presentations at the event.

Neil Gordon, chief executive at Subsea UK, said: The subsea umbilical market has seen a massive growth in recent years, and it is predicted to expand and be part of a multi-billion-pound market. We have developed this conference in direct response to the number of opportunities which exist in subsea umbilicals and created a program which showcases the latest technical advances and knowledge which exists in the sector.

The Subsea UK and UMF conference will take place on Thursday, 21 November at the Chester Hotel, Aberdeen from 9am 7:30pm. A drinks reception is happening the evening before from 6.30pm at the hotel. For more information and to purchase tickets visit: https://www.subseauk.com/1479/subsea-uk-events.

Originally posted here:
Conference to examine opportunities in the subsea umbilical industry - WorldOil

Recommendation and review posted by Bethany Smith

TheCorrosion Monitoring Instrument marketreport [6 Year Forecast 2019-2025] focuses on Major Leading Industry Players, providing info likecompany profiles, product type, application and regions, production capacity, ex-factory price, gross margin, revenue, market share and speak to info.Upstream raw materials and instrumentation and downstream demand analysis is additionally administrated. The Corrosion Monitoring Instrument market business development trends and selling channels square measure analyzed. From a global perspective, It also represents overall Corrosion Monitoring Instrument industry size by analyzingqualitative insights and historical data.

Get Free PDF for more Professional and Technical insights @https://www.researchmoz.us/enquiry.php?type=S&repid=2437567

The study encompasses profiles of major companies operating in the global Corrosion Monitoring Instrument market.Key players profiled in the report on the global Corrosion Monitoring Instrument market includeHoneywell, ClampOn, Emerson, Intertek, Buckleys (UVRAL) Ltd, PT Korosi Specindo, Cosasco, Alabama Specialty Products and so on. Market leaders engage in strategic pricing and product improvement to increase their profit margins.

Scope of Corrosion Monitoring Instrument Market

A corrosion monitoring program provides comprehensive monitoring of all critical components of industrial objects, assets, facilities and plants for signs of corrosion. For reliable operation it is important to identify the location, rate, and underlying causes of corrosion. A corrosion monitoring program identifies any non-conforming alloy components, as these are generally susceptible to accelerated corrosion and can give relatively frequent cause for catastrophic failure.

Corrosion Monitoring can provide significant advantages when integrated into both preventative maintenance and the processes inherent to safety management programs. Based on the results of the Corrosion Monitoring program, informed decisions can be made, not only regarding the remaining life of the object affected by corrosion but also regarding life extension strategies, prospective material selection, and cost-effective methods for remedy of corrosion issues and problems.

This reprot focsues on the instrument market.

In 2019, the market size of Corrosion Monitoring Instrument is xx million US$ and it will reach xx million US$ in 2025, growing at a CAGR of xx% from 2019; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast period.

In this report, 2018 has been considered as the base year and 2019 to 2025 as the forecast period to estimate the market size for Corrosion Monitoring Instrument.

This report studies the global market size of Corrosion Monitoring Instrument, especially focuses on the key regions likeUnited States, European Union, China, and other regions (Japan, Korea, India and Southeast Asia).

This study presents the Corrosion Monitoring Instrument production, revenue, market share and growth rate for each key company, and also covers the breakdown data (production, consumption, revenue and market share) by regions, type and applications. history breakdown data from 2014 to 2019, and forecast to 2025.

For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2014 to 2019.

Get Assistance on this Market Report at:https://www.researchmoz.us/enquiry.php?type=E&repid=2437567

(*Fill the form and our sales representative will get back to you for assistance)

The end users/applications and product categories analysis:

On the basis of product,this report displays the sales volume, revenue (Million USD), product price, market share and growth rate of Corrosion Monitoring Instrument for each type, primarily split into-

On the basis on the end users/applications,this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate of Corrosion Monitoring Instrument for each application, including-

The study objectives of this report are:

You can Purchase This Report from Here @https://www.researchmoz.com/checkout?rep_id=2437567&licType=S

Contact Us:

ResearchMozMr. Nachiket Ghumare,Tel: +1-518-621-2074Toll Free: 866-997-4948 (US-CANADA)Email:[emailprotected]Follow us on LinkedIn @http://bit.ly/2RtaFUo

Follow us on Blogger @https://marketnews-24.blogspot.com/

More here:
Global Corrosion Monitoring Instrument Market 2019 - Industry Key Trends, Growth Prospects and Forecasts to 2025 - Statsflash

Recommendation and review posted by Bethany Smith

Turmeric has numerous uses when it comes to health benefits. They are being used in Indian households for a long time.These include several health benefits and medicinal uses. Turmeric is one of the most powerful spices. It has a unique taste with a mix of citrusy bitterness. It is also associated with Ayurvedic practices.

Also read:Indian Food: What Are The Uses Of Turmeric In Indian Dishes?

Turmeric also has some benefits to enhance your beauty. Its anti-inflammatory properties help in removing dead skin cells. It can also be used to wash your fash or apply once in a while. There are several benefits you can receive from turmeric. These are some of the imperative ones.

Also read:Basil Benefits: Top Benefits Of Basil For Your Skin

The anti-inflammatory properties that are found in turmeric are used to soothe osteoarthritis and rheumatoid arthritis. These collectively work in your favour. The antioxidant destroys the free radicals in the body that damage the cells. These can help alleviate and relax your mild joint pains. It cannot be used as a substitute for medication.

There is a compound in turmeric that has not been studied as much as the other compounds like curcumin - aromatic turmerone or ar-turmerone. This compound has reportedly been repairing brain stem cells. It also helps in the recovery from neurodegenerative diseases like stroke and Alzheimer's.

A substance in turmeric Lipopolysaccharide has anti-bacterial, anti-fungal, and anti-viral agents. This also helps to stimulate the immune system. Make sure you consume only a teaspoon in warm water.

Also read:Jackfruit: Delicious Recipes To Make With The Diabetic Friendly Fruit

The anti-inflammatory and antioxidant properties of curcumin help to reduce the onset of Type 2 diabetes. It helps to moderate insulin levels and boosts the effect of medications that treat diabetes. But always remember not to use it as a source of medication.

Turmeric increases the production of vital enzymes that detoxify our blood in the liver by breaking down and reducing the toxins. It also helps with the circulation of blood. Overall, it is known to improve liver health.

Original post:
Turmeric: Uses and benefits of the spice that you must know - Republic World - Republic World

Recommendation and review posted by Bethany Smith

Humans diverged from chimpanzees and other great apes roughly 6m years ago. But despite us being closely related, human brains are vastly different enabling us to engage in complex language, science, art, morality and much more. But what exactly was it that enabled our brains to reach such mindboggling heights?

We know that the human brain has dramatically expanded in size over the past 6m years. Humans are in fact the mammals with the largest brain relative to body size. But which specific evolutionary genetic changes enabled larger and more complex brains has long remained a bit of a mystery. Now a new study, published in Nature, offers clues.

One important reason why it has been so hard to study primate brain development is that, until relatively recently, scientists did not have access to living, developing brain tissue. This is what can ultimately allow us to functionally test theories of brain evolution as we can essentially watch how a brain develops over time in a dish and manipulate biological pathways to see what role they play in brain development.

But in the last few years, scientists have worked out how to make lab-grown models of developing brain tissue so-called brain organoids to begin to address these questions.

Organoids are clusters of cells that organise themselves into mini versions of our organs, such as the brain or the liver. Thats because they are made by culturing stem cells, which have the potential to develop into any tissue of the body. These stem cells can be generated directly from cells of adult origin, such as skin or blood cells. They are then grown in a gel that allows them to develop three dimensionally. And thats exactly what the researchers behind the new study did.

So what kind of genetic changes do we think contributed to human brain evolution? Only about 1.5% of our DNA actually consists of genes with instructions for making proteins. Proteins are the molecules that do most of the work in cells and determine the cells structure and function. It was once thought that the remaining 98.5% of DNA was junk with no clear purpose. However, it is now known that some of this DNA may play an important role in controlling which genes are expressed meaning determining how they are turned on and off.

The number of changes in protein-coding regions of DNA are far too few to explain the striking differences observed between humans and other primates. In fact, of the genetic regions that have changed the most since our divergence from chimpanzees, 92% do not overlap with protein-coding DNA.

It is predicted that at least a third of these regions play a role in controlling the expression of genes. It has long been hypothesised that the majority of differences observed between the brains of great apes and us are due to changes in the timing and expression of genes, rather than changes to the gene itself. The vast majority of our genes are therefore identical.

The main focus of the new study was to identify how genes are regulated differently in humans compared to other primates. The authors did this by generating brain organoids from human, chimpanzee and macaque stem cells and compared these at various points over the course of four months. This mimics how a brain forms in the womb, with organoids consisting of multiple growing buds of brain tissue that first consist largely of neural progenitor cells that in later stages begin to make neurons.

From the outside, brain organoids look more like small popcorn than a mini brain and do not reach sizes larger than around five or six millimetres due to a lack of blood supply.

The authors observed that human brain development occurs at a slower pace than the other two primates. This delayed maturation of the human brain makes sense as, given more time, the cells that generate neurons will have a longer period to expand their population, giving rise to more neurons and a bigger brain later on.

The researchers were also able to look at the expression of genes in individual cell types of the brain organoids. They measured the expression of a gene by looking at the levels of a messenger molecule that is made from reading DNA and is necessary to direct the formation of proteins. By comparing gene expression in cells that were developing to become the cerebral cortex which plays an important role in advanced cognitive processes such as awareness, thought, memory, language and consciousness they detected 98 genes that were differently expressed in humans.

Gene expression doesnt tell the whole story though. Its rate is ultimately controlled by a process called gene regulation. In order to identify potential regulatory mechanisms, the authors pinpointed regions of DNA that are accessible or open at the various stages in particular cells. These accessible regions of DNA have the potential to interact with proteins and can regulate gene expression.

By comparing organoids between human and chimpanzee, the researchers were able to identify regions of DNA that were differently accessible in humans potentially playing a regulatory role. Regulatory regions of DNA are more likely to be found in close proximity to the genes they are regulating the expression of. More than 60% of the genes that were expressed differently in humans were also in close proximity to differently accessible regions. This suggests that human-specific development and gene expression is a result of evolutionary changes in regions of DNA that are capable of regulating gene expression.

A significant proportion of the regions of DNA that we already know have changed the most since our divergence from chimps were found to overlap with those being different in terms of accessibility suggesting the team has indeed highlighted key regulatory processes responsible for making us humans.

This study takes the first steps in pinpointing interesting candidate genetic regions responsible for human brain complexity. The authors do not dive deeper into the mechanisms of what the altered expression of a specific gene actually means in terms of how the brain grows and functions. It does, however, provide an excellent resource and starting point to direct future research in this direction.

This research is not only important in understanding what makes us human, but also in working out how certain human disorders may arise. Several studies have found that mutations in regions of DNA with human-specific changes are associated with neurodevelopmental disorders.

Excerpt from:
Lab-grown mini brains shed light on how humans split from great apes - The Conversation UK

Recommendation and review posted by Bethany Smith

Some gene therapies, such as bluebird bios Zynteglo, work by modifying a patients own blood stem cells to deliver a functioning gene. While they hold great potential as life-saving treatments for many immune system disorders and blood-based conditions, the process for administration can be costly and time-consuming.

In a study published in the journal Blood, scientists at Scripps Researchdescribed a possible way to more efficiently deliver genes to improve gene therapy treatment outcomesand it involves a close relative to a natural compound found in grapes.

Take Zynteglo, formerly known as LentiGlobin. Approved in the EU to treat beta thalassemia, an inherited blood disorder, it uses a lentiviral vector to insert a functioning version of the beta-globin gene into a patients blood-producing hematopoietic stem cells (HSCs) outside of the body. When the cells are given back to the patient, the gene can multiply and start to make healthy red blood cells.

Industry Insight Survey: Direct-to-Patient Distribution of Clinical Supplies

This industry survey seeks to gain insight on trial sponsors' perspective on offering a DTP option and their current level of awareness and understanding of any factors that may influence their ability to do so. The first 50 qualified respondents will receive a $5 Amazon gift card.

However, HSCs protect themselves with structures known as interferon-induced transmembrane (IFITM) proteins against viral attacks. Therefore, in preparation for a gene therapy, the lentiviral vectors could be intercepted several timeswasting a large amount of expensive materialsbefore a successful delivery.

This is why gene therapy of hemopoietic stem cells has been hit-or-miss, Bruce Torbett, the studys senior author, said in a statement. We saw a way to potentially make the treatment process significantly more efficient.

Torbett and colleagues at Scripps Research focused on caraphenol A, a small molecule related to resveratrol, which is a natural compound produced by grapes widely known for its antioxidant and anti-inflammatory effects.

The team found that adding caraphenol A to human HSCs, along with lentiviral vectors, could reduce the cells natural defenses by lowering the levels of IFITM2 and IFITM3, allowing the vectors to pass more easily. The effect was even more pronounced once the HSCs were transplanted into mice, as the cells divided and produced blood cells with the corrected gene, according to the team.

RELATED:Improving viral vectors for hemophilia gene therapies by tricking the immune system

Because gene therapy holds the promise of a potential cure for debilitating diseases that are deadly or require long-term care, scientists have been exploring new ways to improve it. A research team at the San Raffaele Telethon Institute for Gene Therapy in Italy recently found integrating the protein CD47 in the surface of lentiviral vectors could help them escape detection and destruction by the immune system once inside the body.

Torbett and his team believe caraphenol A could reduce costs of HSC-based gene therapy, which are high: Bluebird has priced Zynteglo at 1.6 million ($1.8 million) in Europe. It could also save time by helping patients get the therapy sooner. And because the longer stem cells stay outside of the body, the more likely they are to lose their ability to self-generate, more efficient gene delivery could also preserve their self-renewing properties, Tobett said.

Read more:
Could a grape-based compound improve gene therapy efficiency? - FierceBiotech

Recommendation and review posted by Bethany Smith

Injecting the gene-editing tool CRISPR into the brains of adolescent mice counteracts the effects of a mutation in a top autism gene. The finding suggests that mutations in this gene, SCN2A, may be treatable at any age.

This gives us hope that this is something thats not just a developmental deficit, and that once all the changes are there that youre stuck with them, says Perry Spratt, a graduate student in Kevin Benders lab at the University of California, San Francisco. Spratt presented the unpublished findings today at the 2019 Society for Neuroscience annual meeting in Chicago, Illinois.

SCN2A encodes a sodium channel that helps neurons propagate electrical signals. The mice have a harmful mutation in one copy of the gene, causing their neurons to fire sluggishly and make immature connections. The treatment reverses the problem by ramping up expression of the intact copy.

The first inkling that the reversal might work even after infancy came in June: The team reported then that introducing an SCN2A mutation into adolescent mice has many of the same effects on neurons as a mutation present from conception.

At the cellular level we see a lot of the same deficits as we see when the genes been gone throughout life, Spratt says.

The team engineered mice in which the mutation in SCN2A can be corrected by injecting an enzyme called Cre recombinase.

Running short: Neurons from mice missing SCN2A (right) have signal-receiving branches that are less mature than those in controls (left).

Injecting the Cre enzyme into the brains of 4- to 5-week-old mutant mice restored normal expression of SCN2A. It also reversed the problems in the mices neurons.

But this strategy cannot be applied to people because it would require genetic engineering of embryos. So the researchers created a virus that ferries a modified version of CRISPR into cells. This version of the editing tool does not snip DNA but can instead activate any gene.

The researchers injected the virus into the brains of 4-week-old mutant mice, along with synthetic RNA snippets designed to guide CRISPR to SCN2A. The treatment boosted SCN2A expression and reversed the problems in the mices neurons.

The team also tested one important control: They found that the treatment does not cause neurons to become hyperactive and so does not run the risk of triggering seizures.

The remarkable thing about this is that it can go gangbusters without making the cells hyperexcitable, says Bender.

The team is testing ways to deliver the virus to the whole brain. They also plan to test whether CRISPR reverses learning and memory problems in the mutant mice.

For more reports from the 2019 Society for Neuroscience annual meeting, please click here.

Read the original here:
CRISPR therapy may reverse autism mutation's effects well past infancy - Spectrum

Recommendation and review posted by Bethany Smith

Fargo, N.D., Oct. 22, 2019 (GLOBE NEWSWIRE) -- Aldevron has announced the immediate availability of Nanoplasmids and antibiotic-free RNA-OUT technology for use in gene therapy manufacturing. Through a license agreement with Nature Technology Corporation (NTC), Aldevron can now provide its clients the option of using NTCs plasmid technology to provide a more efficient system for manufacturing viral vectors used in gene and cell therapy. Gene and cell therapy companies interested in using NTCs technology can now go directly to Aldevron for their manufacturing needs without first obtaining a license from NTC. For applications where the NTC plasmid is not the active pharmaceutical ingredient or in the final product clients do not need to pay any royalties or license fees beyond the purchase price of the product.

Gene and cell therapy researchers continue to make incredible discoveries that will improve lives for millions of people, said Michael Chambers, Aldevron CEO. Aldevron is committed to providing the best manufacturing technologies to support their breakthrough treatments. Our partnership with NTC enables us to provide plasmid technology that significantly improves the manufacturing process and reduces regulatory risk, resulting in reduced costs and faster time to patients.

The fields of gene and cell therapy are surging with the approvals of Kymriah and Yescarta CAR-T treatments for cancer and Luxturna for the treatment of Leber congenital amaurosis, a rare genetic ocular disease. With nearly 3,000 clinical trials underway, improvements in manufacturing are required to provide the capacity to accommodate the growth in research and anticipated commercial products. The NTC technology, combined with Aldevrons unequaled scale and throughput, assure clients will have the products they need.

Our Nanoplasmid and RNA-OUT technology has been under development for 12 years and can provide demonstrable advantages for viral vector manufacturing, said Clague Hodgson, CEO of NTC. We are pleased to collaborate with Aldevron to make this technology immediately available to its clients so they can avoid the delay and expense associated with the licensing process thereby reducing the barriers to delivering transformative treatments to patients.

Providing these novel plasmids furthers our strategy to go beyond the traditional role of a contract development and manufacturing organization, added Chambers. Aldevron provides a variety of options for clients, including off-the-shelf, royalty-free helper plasmids for AAV production and packaging plasmids for lentiviral production, in pursuit of our goal to enable our clients to make a difference in the lives of the patients they serve. For more information on Nanoplasmids, please visitaldevron.com/nanoplasmid.

About Aldevron

Aldevron serves the biotechnology industry with custom production of nucleic acids, proteins, and antibodies. Thousands of clients use Aldevron-produced plasmids, RNA and gene editing enzymes for projects ranging from discovery research to clinical trials to commercial applications. These products are critical raw materials and key components in commercially available drugs and medical devices. Aldevron specializes in GMP manufacturing and is known for inventing the GMP-Source quality system. Company headquarters are in Fargo, North Dakota, with additional facilities in Madison, Wisconsin, and Freiburg, Germany. To learn more, visitwww.aldevron.com.

About Nature Technology Corporation

Nature Technology Corporation is a developer of safe and effective nucleic acid-based gene therapeutics, DNA vaccines, and associated technologies, including antibiotic-free selection (RNA-OUT), regulatory compliance, viral vector retrofitting, and best in class NanoplasmidsTM. NTC proprietary vector and manufacturing platforms offer wide applications to improve the safety and performance of plasmids and biologics. NTC also provides cost effective outsourcing of product development services including custom gene design, vector construction, plasmid DNA manufacturing and recombinant proteins. For more information about NTC products and business related inquiries visitwww.natx.comor contact Deborah Moorad-Watts, email: dmoorad@natx.com.

Original post:
Aldevron, Nature Technology Corporation team up to offer Nanoplasmids for gene therapy manufacturing - GlobeNewswire

Recommendation and review posted by Bethany Smith

In order to help individuals suffering from emotion dysregulation, Stanford Psychophysiology Laboratorys Wehab Lab has developed a haptic breathing pacer (HBP) prototype. The technology also helps those diagnosed with Autism Spectrum Disorder better regulate anxiety levels. (Photo : Pardis Miri)

The Wehab Lab of the Stanford Psychophysiology Laboratory has been working on developing a haptic breathing pacer (HBP) to address issues surrounding mental health and emotion dysregulation, an individuals inability to change an undesired emotional experience. The device applies vibrations to a users body, with which they can synchronize their breathing to reduce arousal in high-stress situations.

Post-graduate researcher Pardis Miri described it as important for helping individuals cope with a stressor.

There is significant recent interest in developing technology that can help people regulate high-arousal negative affect in the course of their everyday lives, she wrote. Negative affect is a personality trait that includes emotions such as anger, anxiety and stress. These technologies have all been designed for a neurotypical population and, for the most part, [are] not well-evaluated for efficacy. The term neurotypical refers to individuals without a developmental disorder.

Technologies being developed by other researchers are not evaluated with consideration for those with individual differences or the neurodiverse population, according to Miri. But Miris team found that their inconspicuous and personalizable breathing pacer prototype could be able to help individuals outside of the neurotypical population, she said.

The prototype proved to be especially promising, Miri wrote, for individuals who score low in terms of two traits: openness, as measured by the Big Five scale, and usage of reappraisal, a psychological strategy that lessens the emotional impact of a stressful event.

These are characteristics commonly observed in Autism Spectrum Disorder (ASD) population, and so our findings suggest potential interventional success for individuals diagnosed with ASD, Miri said.

Helping these children successfully regulate their affect could have a major impact on their development and could prevent them from serious health issues, Miri wrote.

Horia Margarit M.S. 17, a member of the research team, used machine-learning techniques to analyze data collected from the prototypes.

He used a method published in 2017, he said. Very few people even know about it, and thats one of the major triumphs of our research because we were able to show this level of success using that technique.

The team is focusing on improving the efficacy of their pacer for individuals with ASD.

We believe our approach is promising for individuals diagnosed with ASD, and we also understand the risks that are involved, Miri wrote. Our goal is to create a personalizable vibrotactile system that utilizes the strengths of the autistic population to respond to their affect regulatory needs.

Miri said her aim is to demonstrate the efficacy of her teams approach in regulating the affect that individuals diagnosed with ASD experience in their daily lives.

This is tremendously promising research because the entire concept behind this is similar to that of CRISPR and gene therapy: personalized medicine, Margarit said. What Pardis and I did was understanding people on a personal level in terms of mental health.

Contact Camryn Pak at cpak23 at stanford.edu.

We're a student-run organization committed to providing hands-on experience in journalism, digital media and business for the next generation of reporters.Your support makes a difference in helping give staff members from all backgrounds the opportunity to develop important professional skills and conduct meaningful reporting. All contributions are tax-deductible.

Read the original post:
Researchers work on device to help individuals cope with autism - The Stanford Daily

Recommendation and review posted by Bethany Smith